Project Grant K99HL181289
Award Date 8/1/25
Completion Date 6/30/27
Dollars Obligated $169K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Philadelphia, PA 19104, USA
Similar Awards
- This $1,137,498.00 Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) will support research to investigate the regulatory mechanisms involved in cardiac maturation. The primary awardee, The Trustees of the University of Pennsylvania, will conduct this work between April 1, 2025 and March 31, 2032. The research aims to address three key questions: 1) whether naturally-occurring variants in human cardiomyocyte genomic...
- The federal Project Grant award of $117,525.00 from the National Heart Lung and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) is funding research at Boston Children's Hospital to investigate cellular adaptation to perturbations in one-carbon metabolism. The research aims to characterize the role of the UFMylation pathway in maintaining cellular fitness during folate depletion, and explore signaling cascades that promote cellular fitness in response to one-carbon metabolism...
- This federal Project Grant award of $772,808 from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports research into the role of cardiac metabolism and glutamine production in heart failure and cardiac fibrosis. The project, led by Temple University, aims to investigate whether cardiomyocyte glutamine production plays a pivotal role in fibroblast activation and cardiac fibrosis. Key research activities include generating a cardiomyocyte-specific...
- This Project Grant award, valued at $667,704.00, was provided by the National Heart Lung and Blood Institute under the Cardiovascular Diseases Research program (CFDA 93.837) to address hypertrophic cardiomyopathy (HCM), a genetic heart condition affecting 1 in 500 adults. The primary objective is to develop chemically inducible split base editors (SBE) that can precisely and controllably edit the MYBPC3 gene in the heart to correct mutations that cause HCM. The research aims to expand...
- This federal Project Grant award of $169,020.00 was provided by the National Heart Lung and Blood Institute (NHLBI), which operates under the Cardiovascular Diseases Research federal grant program (CFDA 93.837). The grant supports research at the University of Pennsylvania investigating the impact of obesity and diabetes on coronary microvascular defects in heart failure with preserved ejection fraction (HFpEF). The research will use an animal model of HFpEF to compare the temporal progression...
- This $240,552 Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports a research project titled "Unraveling the Cell Networks in Bone Marrow Through Transcriptomic and Epigenetic Profiling" at the University of Pennsylvania. The project aims to generate a comprehensive single-cell transcriptomic and regulomic map of human bone marrow cells and experimentally establish the mesenchymal cell hierarchy in human bone....
- This Project Grant award of $167,400 from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) supports research by Dr. Joshua Meisner at the University of Michigan to elucidate the mechanical and metabolic pathways underlying MYBPC3 hypertrophic cardiomyopathy. The research aims to develop novel in vivo and in vitro models to study the progression of this severe, adolescent-onset heart disease, and test the reversibility of pathology by targeting...
- This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $751,747 to the University of North Carolina at Chapel Hill to conduct research on the role of the protein arginine methyltransferase CARM1 in regulating cardiomyocyte (CM) maturation. The research aims to define key factors and signaling pathways that control CM structural, functional, and electrophysiological maturation at both...
- This federal Project Grant award was provided by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the use of NNMT inhibition to treat heart failure. The $736,089 grant supports research to determine if increased NNMT activity, leading to NAD+ deficiency, is central to the pathophysiology of both heart failure with preserved ejection fraction (HFpEF) and heart failure with reduced ejection fraction (HFrEF). The...
- The federal Project Grant award titled "Lysosomal Ionic Dysregulation in Heart Disease" was provided by the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) to Temple University-Of The Commonwealth System Of Higher Education in Philadelphia, PA. The $717,558 award, which runs from September 4, 2025 to June 30, 2030, will support research to investigate the role of the lysosomal two-pore channel (TPC2) in promoting cardiomyocyte death and impaired...